ARE IgG-ANTI-FAB2ɤ AND IgG-ANTI-HINGE ANTIBODIES ACTIVE
CONSTITUENTS OF INTRAVENOUS IMMUNOGLOBULIN?
DAN NAVOLAN1#*, IOAN SAS1#, PETER TERNESS2
1Department of Obstetrics-Gynaecology and Neonatology, "Victor Babes" University of Medicine and Pharmacy, 3 Odobescu
Street, 300202, Timisoara, Romania
2Department of Transplantation-Immunology, Institute for Immunology, University of Heidelberg, 69120, Heidelberg,
*corresponding author: firstname.lastname@example.org
# All authors have equal contribution.
Download Full Article
Our aim was to find out if immunoglobulins for intravenous use (IVIG) contain IgG-anti-F(ab')2γ (AFab2) and IgG-anti-
Hinge (AH) antibodies (Ab.) and to discuss how AFab2, in particular AH could contribute to immunomodulatory effect of
IVIGs. We measured IgG, AFab2 and AH in five IVIG products approved for therapeutic use. IVIG showed higher AFab2
and AH concentration than sera of randomized healthy controls. Individual IVIG products showed different AFab2 and AH
concentrations. AFab2 and AH were thought to exert an immunosuppressive effect in patients with certain autoimmune
diseases, graft recipients and pregnant women. Since in these cases the disease may be caused by a decreased AFab2 and AH
concentration abrogating the immunotolerance, it is expected that administration of AFab2 and AH containing IVIGs
would reverse the immunotolerance and cure the disease. The data presented herein show for the first time that some IVIGs
contain a significant amount of AFab2 and AH and thus open the door for substitutive therapies of diseases in which these
immunosuppressive antibodies play a pathogenetic role.